PMID- 8170423
OWN - NLM
STAT- MEDLINE
DCOM- 19940527
LR  - 20211203
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 160
IP  - 8
DP  - 1994 Apr 18
TI  - The burden of Haemophilus influenzae type b disease in Australia and an economic 
      appraisal of the vaccine PRP-OMP.
PG  - 483-8
AB  - OBJECTIVES: To estimate the incidence and sequelae of Haemophilus influenzae type 
      b disease (Hib) in the Australian population, and to evaluate the costs and 
      outcomes of a vaccination program using the vaccine PRP-OMP at two, four and 12 
      months. DESIGN: The evaluation was based on a decision analytic model developed 
      by Merck Sharp and Dohme (Australia) Pty Ltd, to predict the number of children 
      who would contract Hib, and suffer mild or severe sequelae or die as a result. 
      The state of health of a cohort of children was modelled each month over a 
      five-year period. A survey of medical records and interviews with parents of 
      children who contracted meningitis in Western Australia from 1984-1990 was 
      undertaken to provide data on the extent and costs of sequelae. RESULTS: The 
      incidence of Hib among non-Aboriginal Australians under five years of age was 
      estimated as 53 per 100,000, and 460 per 100,000 among Aborigines. In a single 
      year at least 630 children may contract Hib, up to 19 may die, and a further 46 
      may have neurological damage, this being severe in up to 18 children. The number 
      of deaths could be reduced by 17 per year and a further 25 cases of severe and 16 
      cases of mild disability could be averted. At a price of $20 per dose, and a 5% 
      discount rate, the expected cost per year of life extended by a vaccination 
      program is $3148. When adjusted for the increased number of years without 
      neurological impairment, the incremental cost per quality adjusted life year 
      (QALY) is $1965. Compared with a single vaccine at 18 months, the incremental 
      cost per additional QALY gained is $5047. A separate analysis of the Aboriginal 
      population showed that the proposed vaccination program would be of significant 
      benefit, leading to a saving of resources.
FAU - Harris, A
AU  - Harris A
AD  - University of Western Australia, Department of Public Health, Queen Elizabeth II 
      Medical Centre, Nedlands.
FAU - Hendrie, D
AU  - Hendrie D
FAU - Bower, C
AU  - Bower C
FAU - Payne, J
AU  - Payne J
FAU - de Klerk, N
AU  - de Klerk N
FAU - Stanley, F
AU  - Stanley F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Bacterial Outer Membrane Proteins)
RN  - 0 (Haemophilus Vaccines)
RN  - 0 (Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer 
      membrane protein conjugate vaccine)
RN  - 0 (Polysaccharides, Bacterial)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
MH  - Age Factors
MH  - Australia/epidemiology
MH  - Bacterial Outer Membrane Proteins/adverse effects/*economics
MH  - Child, Preschool
MH  - Cohort Studies
MH  - *Cost of Illness
MH  - Cost-Benefit Analysis
MH  - *Decision Support Techniques
MH  - Epiglottitis/economics/etiology/microbiology
MH  - Forecasting
MH  - Haemophilus 
      Infections/classification/complications/economics/*epidemiology/*prevention & 
      control
MH  - Haemophilus Vaccines/adverse effects/*economics
MH  - *Haemophilus influenzae/classification
MH  - Humans
MH  - Immunization Schedule
MH  - Incidence
MH  - Infant
MH  - Meningitis, Haemophilus/economics/epidemiology/microbiology
MH  - *Models, Statistical
MH  - *Native Hawaiian or Other Pacific Islander
MH  - Outcome Assessment, Health Care
MH  - Polysaccharides, Bacterial/adverse effects/*economics
MH  - *Population Surveillance
MH  - Program Evaluation
MH  - Quality of Life
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Survival Rate
MH  - Vaccination/adverse effects/*economics/*methods
MH  - Vaccines, Conjugate/*economics
MH  - Value of Life
EDAT- 1994/04/18 00:00
MHDA- 1994/04/18 00:01
CRDT- 1994/04/18 00:00
PHST- 1994/04/18 00:00 [pubmed]
PHST- 1994/04/18 00:01 [medline]
PHST- 1994/04/18 00:00 [entrez]
PST - ppublish
SO  - Med J Aust. 1994 Apr 18;160(8):483-8.